We have demonstrated that type III NKT cells have an innate immunity against acute myeloid leukemia (AML) and identified their subsets with specific markers contributing cytotoxicity and cytokine production selectively to AML cancer cells. Furthermore, recognition of AML cancer cells by type III NKT appears CD1d-independent. Native forms of type III NKT cells without engineering could have the potential to treat patients with AML.